Pain points to potential: Positioning process and analytical development for next-gen cell therapies

As the number of cell therapy products in clinical development increases, so does the need for cell therapy developers to efficiently establish a robust, reliable, and commercial-ready GMP manufacturing and control strategy for their program.

This webinar aims to guide cell therapy developers along their commercial pathway starting with key considerations in development through to IND/CTA filing and lot release.

• Scale-up decisions – how and when to scale-up or scale-out
• Regulatory considerations in setting up an effective phase-appropriate testing strategy
• Process development and analytical development approaches to future-proof early programs and CMC

Sarah Campion

Director, Analytical Development, Charles River Cell Therapy CDMO Services

Alex Sargent

Director, Process Development, Charles River Cell Therapy CDMO Services